IDO1 is highly and constitutively expressed in NSCLC patients and acts as an immune checkpoint induced by potent mediators such as interferon-γ (IFN-γ), transforming growth factor-β (TGF-β), and other proinflammatory signals in the tumor microenvironment [13–16]. Here, TGFB1 is linked to neoplasm.